| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02994784 Details | 2023-05-24 Interventional | 2 | 27 | Melphalan Amyloidosis Immunoglobulin … Amyloidosis; Sy… | Slow Accrual during COVID pandemic, alternative treatments available. Study halted early. Study was halted early resulting in relatively small numbers of participants analyzed. | |||
| NCT04063865 Details | 2023-05-23 Interventional | 3 | 14 | Everolimus Tacrolimus Renal Insuffici… Kidney Failure | Study was larger than expected and became a burden to faculty and staff resources. - | |||
| NCT02382406 Details | 2023-05-23 Interventional | 1/2 | 46 | Carboplatin Paclitaxel Pembrolizumab Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | The study was completed. It was fully accrued. - | |||
| NCT00946712 Details | 2023-05-23 Interventional | 3 | 1333 | Albumin-Bound P… Antibodies Antibodies, Mon… Antineoplastic … Bevacizumab Carboplatin Cetuximab Endothelial Gro… Immunoglobulin … Immunoglobulins Paclitaxel Adenocarcinoma Adenocarcinoma … Carcinoma Lung Neoplasms Recurrence Recurrent Large… Recurrent Lung … Recurrent Squam… Stage IV Large … Stage IV Lung A… Stage IV Squamo… | terminated at pre-planned futility analysis - | |||
| NCT04703426 Details | 2023-05-22 Interventional | 2 | 0 | Pembrolizumab Sargramostim Melanoma Metastatic Mela… Stage III Melan… Stage IV Melano… Unresectable Me… | Study terminated by sponsor - | |||
| NCT04493320 Details | 2023-05-22 Interventional | 4 | 5 | Carbidopa Carbidopa, levo… Levodopa Depression Depressive Diso… Cognitive Impai… Gait Impairment | Study terminated by sponsor (NIMH) Data collected in the trial have been presented as required but are considered unreliable. | |||
| NCT03892018 Details | 2023-05-22 Interventional | 1 | 29 | Paclitaxel Solid Tumor, Ad… | STUDY HALTED DUE TO FINANCIAL CONTRAINTS - | |||
| NCT03761030 Details | 2023-05-22 Interventional | 4 | 51 | Carbidopa Carbidopa, levo… Levodopa Depression Depressive Diso… Depressive Diso… Dysthymic Disor… Dysthymia Major Depressiv… | The project end date was reached prior to the full sample enrollment Data collected in the trial have been presented as required but are considered unreliable. | |||
| NCT02989597 Details | 2023-05-22 Interventional | 4 | 10 | Dexamethasone Ketamine Methadone Remifentanil Sufentanil Pain, Postopera… | Due to personnel loss and logistical issues the study was unable to be completed as planned. - | |||
| NCT04311489 2019-002268-28 Details | 2023-05-18 Interventional | 2 | 17 | Ularitide Ascites Fibrosis Liver Cirrhosis Ascites Hepatic Cirrhosis, Live… | Interim analysis showing safety concerns - | |||
| NCT05044936 Details | 2023-05-17 Interventional | 1 | 0 | Cannabidiol Muscle Damage | The researchers were not able to acquire funding to initiate the study. Also, the study was not
approved by the local IRB which requested a FDA new drug application. - | |||
| NCT04942340 Details | 2023-05-17 Interventional | 1 | 0 | Atipamezole Caffeine Dexmedetomidine Emergence From … | Withdrawn secondary to a change in protocol design forthcoming. - | |||
| NCT02203773 2014-000687-18 Details | 2023-05-16 Interventional | 1 | 212 | Azacitidine Decitabine Posaconazole Venetoclax Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myelogeno… Myelogenous Leu… Treatment Naive… | Strategic considerations - | |||
| NCT05467761 Details | 2023-05-15 Interventional | 1 | 0 | Psilocybin Healthy | Sponsor was not financially able or willing to continue to support the study - | |||
| NCT03997097 Details | 2023-05-15 Interventional | 3 | 0 | Sildenafil Citr… Heart Diseases Hypertension Hypertension, P… Univentricular … Pulmonary Hyper… Single-ventricl… | New sponsor - | |||
| NCT03435458 Details | 2023-05-15 Interventional | 3 | 429 | Misoprostol Obesity, Matern… Maternal Obesit… | interim analyses - | |||
| NCT02345330 Details | 2023-05-15 Interventional | 2 | 4 | Interleukin-12 Carcinoma Carcinoma, Squa… Squamous Cell C… Head and Neck S… | Due to company resource constraints - | |||
| NCT01579318 Details | 2023-05-15 Interventional | 2 | 2 | Interleukin-12 Lymphoma Lymphoma, T-Cel… Mycoses Mycosis Fungoid… Cutaneous T Cel… Mycosis Fungoid… | Due to company resource constraints Study enrollment was prematurely terminated under protocol version 6.0. No patients signed informed consent under version 7.0. Two (2) of the targeted 27 patients were enrolled. Thus, a formal statistical analysis was not performed. | |||
| NCT04745351 2020-005416-22 Details | 2023-05-12 Interventional | 3 | 249 | Remdesivir COVID-19 | The study was terminated due to study enrollment feasibility. This decision is not based on
efficacy or safety concerns. - | |||
| NCT04591002 Details | 2023-05-12 Interventional | 2 | 0 | Osimertinib Lung Cancer | Further consultation is required, we plan to submit it again as a new project and proceed. - |